- Email: [email protected]
Antibody for detection and quantification of trifluralin
Nucl. Int.
Med. Biol. J. Radiat.
Pergsmon Press
Vol.16. Appl. plc.
t&J,
Inrtrum. Printed
pp.l-iv. Part
1969
B
in Great
Britain
NEW PATENTS This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH” online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH@ can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive, McLean, Virginia 22102 U.S.A. Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon Orbit InfoLine only.
4775638 SINGLE VIAL TECHNIQUE FOR RADIOLABELING PROTEIN Hidde J Haisma, Utrecht, Netherlands assigned to Centocor Inc A method for radiolabeling protein such as antibody which is performed in a single reaction vessel is described. A sealed reaction vessel having a port for addition and withdrawal of reagents preferably by syringe is used. Reagents for coupling radioisotope to the protein are added to the vessel. For radioiodination procedures, vessels can be pre-coated with the iodine coupling agent iodgen. The protein and the radioisotope are then added to the vessel and the radiolabel reaction allowed to proceed. After the reaction is complete, a resin is added to the vessel to adsorb the uncoupled radioisotope. The entire reaction mixture is then withdrawn from the vessel and the resin is separated from the protein preferably by sterile filtration.
4778472 METHOD OF ISOLATING RADIOACTIVE PERRHENATE OR PERTECHNETATE FROM AN AQUEOUS SOLUTION Edward Deutsch, Jean-Lu Vanderheyden signed to University of Cincinnati
as-
Pure perihenate is isolated from a aqueous crude solution of perrhenate by first associating the perrherate with a lipophilic counter ion such as tetrabutyl ammonium. This is added to the solution in a form such as tetrabutyl ammonium bromide. Tetrabutyl ammonium perrhenate is formed. The aqueous mixture is then added to a
reverse phase separation column such as a Cl8 Sep Pak filter which has been previously loaded with the lipophilic counter ion. The aqueous portion of the crude mixture is eluted from the column with water. Subsequently the purified perrhenate associated with the lipophilic counter ion is removed with a less polar solvent such as ethanol. Pertechnetate can also be separated from an aqueous mixture in the same manner. These procedures are particularly suited for isolating relatively pure radioactive forms of perrhenate and pertechnetate such as Re18604-, Re18804-. and 99mTc04-.
4780408 ANTIBODY FOR DETECTION AND QUANTIFICATION OF TRIFLURALIN Bohn Dunbar, Gordon Niswender, James Hudson assigned to Colorado State University Research Foundation An antibody specific to trifiuralin can be produced by first substituting a soluble, straight chain amino acid for a propyl group of alpha, alpha, alpha-trifluoro-2,6-dinitro-N-N-dipropylp-toluidine. The trifluoro group at the 4 position, the nitro group at the 2 position and the other nitro group at the 6 position are left exposed. Thereafter, the resulting substitution product is conjugated, at the site of the substituted amino acid group, with a lysine-rich protein. The resulting compound is then used as an antigen to evoke an immune response in a host animal or antibody producing cell line. The antibody produced against the antigen is then harvested and used in an assay such as a radioimmunoassay or enzyme linked immunosorbant assay (ELISA) to determine the presence and concentrations of
New Patents
ii
trifluralin in agriculturally significant substances such as plant materials, soil and water or to otherwise test for trifluralin contamination of water, food and air.
4780420 PROGESTERONE RECEPTOR LIGANDS Richard Hochberg, William Rosner, Hoyte assigned to Yale University
Robert
Radiodinated and non-radiodinated 16 alphaiodoand 17 alpha-(2-iodovinyl)- 19nortestosterones are prepared and are used in progesterone receptor assays.
4781912 CATIONIC COMPLEX OF TECHNETIUM-99M. Giuseppe D Zanelli, Frank Brady, Niranjan Patel, Aviji Lahiri, Harrow, United Kingdom assigned to Mallinckrodt Inc The invention relates to a cationic complex of technetium-99m with (a) at least one bidendate ligand X having the formula See Patent for Tabular Presentation PS where each Z is phosphorus or arsenic, Q is a (CH2)n linking group where n is 2 to 8 or a 1,Zphenylene linking group, each of RI, R2, R3 and R4 is hydrogen, Cl to C.5 alkyl or phenyl; and (b) at least one monodentate isonitrile ligand Y. The invention also relates to a radiopharmaceutical composition comprising said complex, to a kit for preparing said composition, and to the use of said composition for a radiodiagnostic examination.
4782233 MULTIFIELD COLLIMATOR SYSTEM AND METHOD AND RADIONUCLIDE EMISSION TOMOGRAPHY CAMERA USING SAME Sebastian Genna, Andrew P Smith assigned to Digital Scintigraphics Inc A multifield collimator system and radionuclide emission tomography camera using same which include at least two collimator segments whose
fields of view in combination define at least two tomographic field of view boundaries. At least one of the boundaries encompasses the region to be imaged of an object. The fields of view may overlap at least in part to produce enhanced imaging sensitivity in the portion of overlap. The tomography camera detects radionuclide emissions from the region to collect at least one collimated image through each segment and combines the collimated images to produce a final image of the region exhibiting enhanced sensitivity in the portion of overlap. A multifield method of collimation is also disclosed.
4782840 METHOD FOR LOCATING, DIFFERENTIATING, AND REMOVING NEOPLASMS Edward W Martin, Marlin 0 Thurston assigned to Neoprobe Corporation The present invention is addressed to a method for the improved localization, differentiation, and removal of neoplastic tissue in animals. In particular, one aspect of the present invention involves a surgical procedure wherein an animal suspected of containing neoplastic tissue is surgically accessed and the tissue therein examined visually and by palpation for evidence of neoplastic tissue. The improved methodology commences with the administering to the animal of an effective amount of a labelled antibody specific for neoplastic tissue and labelled with a radioactive isotope exhibiting specific photon emissions of energy levels. Next, and importantly, the surgial procedure is delayed for a time interval following said administering for permitting the labelled antibody to preferentially concentrate in any neoplastic tissue present in the animal so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in said animal. Thereafter, an operative field of the animal is surgically accessed and tissue within the operative field to be examined for neoplastic tissue has the background photon emission count determined. Once the background photon emission account for tissue within the operative field has been determined, a handheld probe is manually positioned within the operative field adjacent tissue suspected of being neoplastic. The probe is configured for fascile hand positioning and maneuvering within the operative field of the animal. The probe is characterized by having a collimatable radiation detector having a selective photon entrance and having an output deriving
Med. Biol. J. Radiat.
Pergsmon Press
Vol.16. Appl. plc.
t&J,
Inrtrum. Printed
pp.l-iv. Part
1969
B
in Great
Britain
NEW PATENTS This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH” online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH@ can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive, McLean, Virginia 22102 U.S.A. Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon Orbit InfoLine only.
4775638 SINGLE VIAL TECHNIQUE FOR RADIOLABELING PROTEIN Hidde J Haisma, Utrecht, Netherlands assigned to Centocor Inc A method for radiolabeling protein such as antibody which is performed in a single reaction vessel is described. A sealed reaction vessel having a port for addition and withdrawal of reagents preferably by syringe is used. Reagents for coupling radioisotope to the protein are added to the vessel. For radioiodination procedures, vessels can be pre-coated with the iodine coupling agent iodgen. The protein and the radioisotope are then added to the vessel and the radiolabel reaction allowed to proceed. After the reaction is complete, a resin is added to the vessel to adsorb the uncoupled radioisotope. The entire reaction mixture is then withdrawn from the vessel and the resin is separated from the protein preferably by sterile filtration.
4778472 METHOD OF ISOLATING RADIOACTIVE PERRHENATE OR PERTECHNETATE FROM AN AQUEOUS SOLUTION Edward Deutsch, Jean-Lu Vanderheyden signed to University of Cincinnati
as-
Pure perihenate is isolated from a aqueous crude solution of perrhenate by first associating the perrherate with a lipophilic counter ion such as tetrabutyl ammonium. This is added to the solution in a form such as tetrabutyl ammonium bromide. Tetrabutyl ammonium perrhenate is formed. The aqueous mixture is then added to a
reverse phase separation column such as a Cl8 Sep Pak filter which has been previously loaded with the lipophilic counter ion. The aqueous portion of the crude mixture is eluted from the column with water. Subsequently the purified perrhenate associated with the lipophilic counter ion is removed with a less polar solvent such as ethanol. Pertechnetate can also be separated from an aqueous mixture in the same manner. These procedures are particularly suited for isolating relatively pure radioactive forms of perrhenate and pertechnetate such as Re18604-, Re18804-. and 99mTc04-.
4780408 ANTIBODY FOR DETECTION AND QUANTIFICATION OF TRIFLURALIN Bohn Dunbar, Gordon Niswender, James Hudson assigned to Colorado State University Research Foundation An antibody specific to trifiuralin can be produced by first substituting a soluble, straight chain amino acid for a propyl group of alpha, alpha, alpha-trifluoro-2,6-dinitro-N-N-dipropylp-toluidine. The trifluoro group at the 4 position, the nitro group at the 2 position and the other nitro group at the 6 position are left exposed. Thereafter, the resulting substitution product is conjugated, at the site of the substituted amino acid group, with a lysine-rich protein. The resulting compound is then used as an antigen to evoke an immune response in a host animal or antibody producing cell line. The antibody produced against the antigen is then harvested and used in an assay such as a radioimmunoassay or enzyme linked immunosorbant assay (ELISA) to determine the presence and concentrations of
New Patents
ii
trifluralin in agriculturally significant substances such as plant materials, soil and water or to otherwise test for trifluralin contamination of water, food and air.
4780420 PROGESTERONE RECEPTOR LIGANDS Richard Hochberg, William Rosner, Hoyte assigned to Yale University
Robert
Radiodinated and non-radiodinated 16 alphaiodoand 17 alpha-(2-iodovinyl)- 19nortestosterones are prepared and are used in progesterone receptor assays.
4781912 CATIONIC COMPLEX OF TECHNETIUM-99M. Giuseppe D Zanelli, Frank Brady, Niranjan Patel, Aviji Lahiri, Harrow, United Kingdom assigned to Mallinckrodt Inc The invention relates to a cationic complex of technetium-99m with (a) at least one bidendate ligand X having the formula See Patent for Tabular Presentation PS where each Z is phosphorus or arsenic, Q is a (CH2)n linking group where n is 2 to 8 or a 1,Zphenylene linking group, each of RI, R2, R3 and R4 is hydrogen, Cl to C.5 alkyl or phenyl; and (b) at least one monodentate isonitrile ligand Y. The invention also relates to a radiopharmaceutical composition comprising said complex, to a kit for preparing said composition, and to the use of said composition for a radiodiagnostic examination.
4782233 MULTIFIELD COLLIMATOR SYSTEM AND METHOD AND RADIONUCLIDE EMISSION TOMOGRAPHY CAMERA USING SAME Sebastian Genna, Andrew P Smith assigned to Digital Scintigraphics Inc A multifield collimator system and radionuclide emission tomography camera using same which include at least two collimator segments whose
fields of view in combination define at least two tomographic field of view boundaries. At least one of the boundaries encompasses the region to be imaged of an object. The fields of view may overlap at least in part to produce enhanced imaging sensitivity in the portion of overlap. The tomography camera detects radionuclide emissions from the region to collect at least one collimated image through each segment and combines the collimated images to produce a final image of the region exhibiting enhanced sensitivity in the portion of overlap. A multifield method of collimation is also disclosed.
4782840 METHOD FOR LOCATING, DIFFERENTIATING, AND REMOVING NEOPLASMS Edward W Martin, Marlin 0 Thurston assigned to Neoprobe Corporation The present invention is addressed to a method for the improved localization, differentiation, and removal of neoplastic tissue in animals. In particular, one aspect of the present invention involves a surgical procedure wherein an animal suspected of containing neoplastic tissue is surgically accessed and the tissue therein examined visually and by palpation for evidence of neoplastic tissue. The improved methodology commences with the administering to the animal of an effective amount of a labelled antibody specific for neoplastic tissue and labelled with a radioactive isotope exhibiting specific photon emissions of energy levels. Next, and importantly, the surgial procedure is delayed for a time interval following said administering for permitting the labelled antibody to preferentially concentrate in any neoplastic tissue present in the animal so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in said animal. Thereafter, an operative field of the animal is surgically accessed and tissue within the operative field to be examined for neoplastic tissue has the background photon emission count determined. Once the background photon emission account for tissue within the operative field has been determined, a handheld probe is manually positioned within the operative field adjacent tissue suspected of being neoplastic. The probe is configured for fascile hand positioning and maneuvering within the operative field of the animal. The probe is characterized by having a collimatable radiation detector having a selective photon entrance and having an output deriving